VCYT

Veracyte, Inc. (VCYT)
Healthcare • Diagnostics & Research • $42.53 • MCap: 3,419,017,472 🌐
https://www.veracyte.com • Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Buy Decision Core
Total Score
59
Business Quality
22
Financial Strength
17
Growth Outlook
5
Momentum
2
Price Action
Current
42.53
52W High
60.49
52W Low
30.01
Above 50DMA
50.71 (-16.13%)
Above 200DMA
42.65 (-0.28%)
Relative Strength
Relative Strength
0.04
RS 3M
-0.13
RS 6M
0.26
RS 9M
-0.11
RS 12M
0.33
Fundamentals
Revenue Growth
0.16%
Earnings Growth
0%
ROE
0.09%
ROA
0.04%
Valuation
PE (Fwd)
21.83
PEG
0
P/B
2.46
Upside
35.95%
Risk
Beta
1.93
Short %
0.10
Risk Score
3.00
Analyst
Rating
none
Target
57.82
Beta
1.93
Analysts
0


Total Score
59
Upside
35.95%
Relative Strength
0.04
Beta
1.93
Why Buy?
  • PEG Ratio below 1 (attractive valuation)
  • Analyst upside exceeds 15%
Key Risks
  • High volatility (Beta > 1.5)
Score Breakdown
Business
22
Financial
17
Growth
5
Valuation
11
Risk
0
Momentum
2
Technical
52W High: 60.49
52W Low: 30.01
Above 50DMA: -16.13%
Above 200DMA: -0.28%
Valuation
Forward PE: 21.83
PEG: 0
P/B: 2.46
Upside: 35.95%
Risk
Beta: 1.93
Short Float: 0.10%
ROE: 0.09%
ROA: 0.04%